- Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01420-3/fulltext 4 comments science
Linked pages
- AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets | European Medicines Agency https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood 83 comments
- ClinicalTrials.gov https://clinicaltrials.gov 35 comments